Phytochemical, Chemotaxonomic and Bioinformatics Study on Laportea Bulbifera (Urticaceae)
May 2022
in “
Chemistry & biodiversity
”
TLDR *Laportea bulbifera* contains unique compounds that may help treat benign prostatic hyperplasia.
The study on *Laportea bulbifera* identified 17 compounds, including flavonoids, terpenoids, phenolic acids, coumarins, steroids, and alkaloids. Notably, some compounds were isolated for the first time from the Urticaceae family and the genus *Laportea*. The research highlighted the chemotaxonomic significance of certain compounds, suggesting that isoflavones could distinguish between species of *L. bulbifera* and the genus *Urtica*. Molecular docking showed that several compounds had a better inhibitory effect on human steroid 5α-reductase 2 (SRD5α2) than finasteride, indicating potential for treating benign prostatic hyperplasia (BPH). This study supports future phytochemical and chemotaxonomic research on *Laportea* and its therapeutic applications.